Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2001

View Archived Issues

Aventis updates 2000 achievements and highlights emerging pipeline products

Introgen and Texas Heart Institute to study gene therapy for cardiovascular indications

Epix and InSightec begin alliance for development of antitumor treatment

Structured treatment interruptions with Remune in HIV-infected patients

ACC news: novel calcium channel antagonist shows potential in atrial fibrillation

Pathways involved in myocardial protective effect of new NHE inhibitor examined in pigs

Picovir shows efficacy for VRI treatment in pivotal studies

Novo Nordisk reports product pipeline progress

Na+/Ca2+ inhibition associated with both neuroprotective and cardioprotective effects

Cardiovascular effects of long-term treatment with AGE crosslink breaker in SHR

Mechanism of beneficial effects of spironolactone in CHF patients under investigation

Amgen's ARANESP recommended for approval by CPMP

Prophylactic mucosal vaccine against RSV effective and safe in mice

Tricyclic immunosuppressive and antiallergic compounds developed at Shionogi

New agents for HCV infection patented by DuPont scientists

Merck describes synthesis and use of new inhibitors of Ras prenylation

Potent and selective vesamicol receptor ligands from Daiichi Radioisotope and use in diagnosis

Boehringer Ingelheim identifies new succinate cathepsin inhibitors

Banyu presents new series of biarylurea CDK inhibitors as antineoplastic agents

AnorMED begins new phase I study of AMD-3100 at University of Washington

International patent covers new Pharmacia oxazolidinones

Bronchodilating effects reported for BM-531 at this week's AAAAI meeting

Arrow Therapeutics' novel antibiotic enters full development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...